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Objectives
We investigated whether age modified associations between markers of HIV progression, CD4
T lymphocyte count and HIV RNA viral load (VL), and the following markers of metabolic
function: albumin, haemoglobin, high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C) and total cholesterol (TC).
Methods
A retrospective analysis of data from the United Kingdom Collaborative HIV Cohort was carried
out. Analyses were limited to antiretroviral-naïve subjects to focus on the impact of HIV disease
itself. A total of 16670 subjects were included in the analysis. Multilevel linear regression
models assessed associations between CD4 count/VL and each of the outcomes. Statistical
tests for interactions assessed whether associations differed among age groups.
Results
After adjustment for gender and ethnicity, there was evidence that lower CD4 count and higher
VL were associated with lower TC, LDL-C, haemoglobin and albumin concentrations but higher
triglyceride concentrations. Age modified associations between CD4 count and albumin
(P < 0.001) and haemoglobin (P = 0.001), but not between CD4 count and HDL-C, LDL-C and TC,
or VL and any outcome. Among participants aged < 30, 30–50 and > 50 years, a 50 cells/μL
lower CD4 count correlated with a 2.4 [95% confidence interval (CI) 1.7–3.0], 3.6 (95% CI
3.2–4.0) and 5.1 (95% CI 4.0–6.1) g/L lower haemoglobin concentration and a 0.09 (95% CI
0.07–0.11), 0.12 (95% CI 0.11–0.13) and 0.16 (95% CI 0.13–0.19) g/L lower albumin
concentration, respectively.
Conclusions
We present evidence that age modifies associations between CD4 count and plasma albumin and
haemoglobin levels. A given reduction in CD4 count was associated with a greater reduction in
haemoglobin and albumin concentrations among older people living with HIV. These findings
increase our understanding of how the metabolic impact of HIV is influenced by age.
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Introduction
The number and proportion of older people living with HIV
infection are increasing. It is predicted that by 2015 half
of the people living with HIV in the USA will be aged 50
years or above [1]. In the UK, the proportion of people
living with HIV who are aged > 50 years increased from
12% in 2002 to 22% in 2011, a phenomenon that is thought
to be associated with both increased survival and increas-
ing incidence of new infections among older individuals
[2]. In the setting of effective antiretroviral therapy (ART),
non-AIDS-related disease has become the predominant
cause of mortality among people living with HIV [3]. HIV
disease progression, as indicated by a reduced CD4 T lym-
phocyte cell count and increased HIV RNA viral load (VL),
is associated with derangement in some markers of meta-
bolic function, specifically lower plasma albumin concen-
tration [4], lower haemoglobin concentration [5], and
higher plasma triglyceride but lower plasma total choles-
terol (TC) and high-density lipoprotein cholesterol (HDL-C)
levels [6]. While older age is associated with an increased
risk of many non-AIDS-related causes of morbidity and
mortality, independently of HIV infection, there are no data
describing whether the impact of HIV disease progression
on markers of metabolic function is greater among older
people living with HIV compared with their younger
peers.
There is evidence that age modifies the impact of HIV
disease on immunological function. For instance, CD4 cell
count declines are more rapid following HIV infection
among older people living with HIV disease [7] and older
age is also associated with an increased risk of AIDS-
related morbidity after adjusting for the CD4 count [8].
CD4 cell count and HIV VL are used by clinicians to
indicate the stage of HIV infection and guide ART deci-
sions. Understanding how infectious and noninfectious
consequences of HIV infection at a given CD4 count/HIV
VL differ between older and younger people living with
HIV may influence the interpretation of these markers in
different age groups. In this paper, we investigate whether
age modifies associations between markers of HIV disease
progression (CD4 count/HIV VL) and plasma albumin,
haemoglobin and plasma lipid concentrations.
Methods
Data from the United Kingdom Collaborative HIV Cohort
(UK CHIC) Study were used in this analysis. The UK CHIC
Study is an observational cohort study of HIV-infected
individuals aged over 16 years attending some of the largest
HIV clinical centres in the UK from January 1996 onwards
[9]. All ART-naïve subjects with at least one visit between
1996 and 2011 were included in the analysis. Analyses were
limited to ART-naïve individuals to focus on the impact
of HIV disease, rather than ART-associated derangements,
on the outcomes being assessed. To allow for possible
miscoding of ART status, apparently ART-naïve individuals
with an HIV VL of < 1000 HIV-1 RNA copies/mL were
assumed to be receiving ART and were excluded from
analyses. Those with a CD4 count > 1000 cells/μL were
excluded for the same reason.
Data were analysed in STATA v12 (StataCorp LP, College
Station, Texas, USA). Multilevel mixed effects linear regres-
sion models were used to assess the associations between
markers of HIV progression (CD4 count/HIV VL) and the
following outcomes: haemoglobin, albumin, low-density
lipoprotein cholesterol (LDL-C), HDL-C, TC and triglycerides.
Data on whether plasma lipid concentrations were fasting or
nonfasting were not available. For each outcome measure, we
identifiedmeasures of the exposure of interest within a 90-day
window. Each resulting exposure/outcome ‘pair’ was included
in the analysis as a separate observation. Where a single
exposure measure was paired to multiple measures of the
outcome, all resulting pairswere included in analysis. Random
intercepts were introduced into the models at the participant
level (level 3) and at the outcome level (level 2) to account
for multiple observations from each participant and multiple
measures of outcome mapped to a single exposure. Each
model included themain effect of age (stratified as< 30, 30–50
and > 50 years), CD4 count and HIV VL and included adjust-
ment for gender and ethnicity. To investigate whether age
modified the associations between CD4 count/HIV VL and
each outcome, analyseswere performed separately in each age
group, and formal tests of interaction were used to assess the
significance of any differences in the associations among age
groups.
The UK CHIC Study was approved by a multicentre
research ethics committee and by local ethics committees.
Results
A total of 16670 subjects (78.9% male) contributed 38261
observations to the overall cohort. At the time of entry into
the cohort, 23.1% were aged < 30 years, 68.7% were aged
30–50 years and 8.2% were > 50 years of age. The majority
of participants self-classified as being of White (59.7%), Black
African (20.5%) or Black ‘other’ (5.3%) ethnicity, with the
remaining patients self-identifying as being of South Asian
(0.8%) or ‘other’ (13.8%) ethnicity. The median (interquartile
range) CD4 count and HIV VL at the time of entry into the
cohort were 320 (180–487) cells/μl and 4.58 (3.81–5.17) log10
copies/mL, respectively. The median (interquartile range) con-
centration of each outcome was: albumin, 39 (33.0–44.0) g/L;
haemoglobin, 127 (106–142) g/L; TC, 4.0 (3.5–4.9) mmol/L;
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LDL-C, 2.1 (2.0–3.0) mmol/L; HDL-C, 1.0 (0.9–1.3) mmol/L;
and triglyceride, 1.3 (1.0–2.0) mmol/L.
Associations with metabolic markers in the
unstratified analysis
After adjustment for gender and ethnicity, there was evidence
that lower CD4 count and higher HIV VL were associated with
lower TC, LDL-C, haemoglobin and albumin concentrations
but higher triglyceride concentrations (Table 1). Older age was
associated with lower haemoglobin and plasma albumin and
HDL-C concentrations, but higher TC, LDL-C and triglyceride
concentrations.
Effect modification of associations by age
In the adjusted analysis, there was evidence that age modi-
fied the associations between CD4 count and haemoglobin
(interaction P = 0.001) and between CD4 count and albumin
(interaction P < 0.001; Fig. 1). In particular, the estimated
impact of a 50 cells/μL lower CD4 count on haemoglobin
was a reduction of 2.4 [95% confidence interval (CI) 1.7–
3.0], 3.6 (95% CI 3.2–4.0) and 5.1 (95% CI 4.0–6.1) g/L in
those aged < 30, 30–50 and > 50 years, respectively. The
estimated impact of a 50 cells/μL lower CD4 count on
albumin was a reduction of 0.09 (95% CI 0.07–0.11), 0.12
(95% CI 0.11–0.13) and 0.16 (95% CI 0.13–0.19) g/L in those
aged < 30, 30–50 and > 50 years, respectively. There was
no evidence in the adjusted analysis that age modified the
association between CD4 count and TC (P = 0.40), LDL-C
(P = 0.84), HDL-C (P = 0.94) or triglyceride (P = 0.15) con-
centration, or the association between HIVVL and any of the
markers of metabolic function.
Discussion
Data from this large cohort study support the previously
reported finding that deterioration in CD4 count and
increasing HIV VL are associated with lower haemoglobin
and albumin concentrations and greater derangement
in plasma lipids. We are the first to present evidence that
age modifies the association between the CD4 count and
plasma albumin and haemoglobin levels; a given reduction
in CD4 count was associated with a greater reduction in
haemoglobin and albumin concentrations among older
people living with HIV. Previously published work has
suggested that haemoglobin and albumin are independent
prognostic indicators in the presence of HIV infection [4,5].
Although we found evidence that worsening markers of
HIV progression were associated with greater derangement
in lipids, we did not find evidence that age modified these
associations. One possible explanation for these negative
findings could be a lack of power; our exploratory analyses Ta
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Fig. 1 Age-stratum-specific estimates of associations between CD4 T lymphocyte count and albumin, haemoglobin, triglyceride, total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) concentrations. β represents the predicted effect
of a 50 cells/μL increase in CD4 count on each outcome from a multilevel linear regression model adjusted for gender and ethnicity. 95% confidence
intervals of estimates are also displayed. Separate estimates are given for participants aged < 30 years (Δ), 30–50 years (□) and > 50 years (◊).
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support (nonsignificant) trends towards bigger increases
in TC, smaller increases in LDL-C and greater decreases in
triglyceride in the older age groups.
There is evidence that untreated HIV infection is associ-
ated with increased cardiovascular risk, but data regarding
whether progressive deterioration in CD4 count increases
cardiovascular risk remain inconsistent [10]. The mecha-
nisms by which HIV increases the risk of cardiovascular
disease are debated. Our finding that HIV progression
is associated with elevated plasma triglyceride concen-
trations would support the theory that HIV-associated
triglyceridaemia plays an important role, although another
study has suggested that the independent impact of triglyc-
eride on cardiovascular risk among people living with HIV is
small [11]. It is also argued that HIV-associated cardiovas-
cular risk may partially be mediated by HIV-specific path-
ways such as immune activation [12]. Our study goes
some way towards supporting this theory by providing
evidence that markers of more advanced HIV disease were
associated with a reduction in the plasma concentration
of lipids such as LDL-C, a traditional risk factor for cardio-
vascular disease.
This study benefits from the large sample size of the UK
CHIC Study. Limiting the analysis to ART-naïve patients
also allowed us to assess the impact of the CD4 count and
HIV VL independently of the impact of ART. There are
limitations to this study, however. Data were analysed
cross-sectionally, we therefore cannot assume a temporal
association that changes in exposure preceded changes in
outcome. We cannot exclude the possibility of unmeasured
confounding as a result of a differential distribution of
traditional risk factors for anaemia, hypoalbuminaemia
or dyslipidaemia. Data were also lacking on the use of
nonantiretroviral medications such as co-trimoxazole,
which are more commonly prescribed among those with a
low CD4 count and can be associated with adverse effects
such as anaemia.
We did not adjust for recent opportunistic infection (OI)
in this analysis, as OI was considered to be on the causal
pathway between progressive HIV disease and the out-
comes; it is possible that some of the apparent associations
between progressive HIV disease and the measured out-
comes were mediated through OI. Despite the large size of
this cohort, there were fewer data for those aged over 50
years compared with the other age groups, limiting our
ability to perform stratified analysis; there were also fewer
data on plasma lipid profiles of this cohort than the other
markers being assessed, raising the possibility that the
study was under-powered to detect interactions with
age when plasma lipid concentrations were the outcome
assessed. Exclusion of participants with a CD4 count
> 1000 cells/μL and/or a HIV VL < 1000 copies/mL reduced
the risk that ART-experienced patients who may have
been misclassified in the database were included in this
analysis, but may have resulted in the exclusion of HIV
elite controllers.
We complement the previously published finding that
age modifies the impact of HIV disease on immunologi-
cal function with evidence that age may also modify the
impact of HIV on noninfectious pathology. CD4 counts are
used by guidelines to guide ART decisions and by clinicians
as a marker for the degree of HIV-associated disease that is
likely to be seen. Our findings reinforce the importance of
considering age in the interpretation of CD4 cell counts
at both the individual and population levels. Further
research to confirm these findings and to assess whether
the changes in metabolic markers seen in this study are of
clinical relevance is justified.
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